自2010年下半年开始，各大企业的7-ACA巨资项目陆续开工及投产的消息不断传出后，7-ACA的市场态势引起了业界的高度关注。据最新的海关数据显示，今年上半年，7-ACA系列中的强势原料药中间体品种的出口下滑，与去年同期相比，7-ACA、头孢唑林、头孢曲松均为负增长；GCLE系列的两个主要品种——GCLE、头孢克肟也呈现大幅度下降趋势，只有7-ADCA系列品种出口有所增长。

Since the second half of 2010 began，Each big enterprise 7-ACA huge projects are put into production starts and the news spread，7-ACA market situation caused by the height of industry attention。According to the latest customs data shows，In the first half of this year，7-ACA series of drug intermediates varieties of strong export slowdown，Compared with the same period last year，7-ACA、cefazolin、Ceftriaxone are negative growth；GCLE series of two main products-GCLE、Cephalosporins g also presents the latter big declines，Only seven-ADCA series varieties increase exports。

　　笔者预计，今年下半年，业界所面临国内外形势将更加严峻，国内整顿抗生素使用工作将引发部分品种的市场萎缩，一些大宗品种（基本药物类）则仍然处于产能过剩价格低迷的局面。而国际市场抗生素的需求保持稳定，能转到中国采购的国外厂商差不多都已经涉足。由此推测，头孢类原料出口的增长空间有限。

The author is expected to，The second half of this year，Facing the industry will be more severe situation at home and abroad，The antibiotic use domestic work will trigger a partial variety market atrophy，Some large varieties（Of basic drugs）It is still in the doldrums of the excess capacity price situation。And the international market the demand of antibiotics remained stable，Can turn to the procurement of almost all foreign manufacturers have involved。At that，Cephalosporin raw material export growth space is limited。